case_images: PMC8366200_01
case_images: Change in central macular thickness (CMT) relative to baseline after PRP.
case_images: 10.1177_25158414211035860-fig1.jpg
case_images: PMC8366200_01_10.1177_25158414211035860-fig1.jpg
case_images: fig1-25158414211035860
case_images: Change in central macular volume at 3 mm relative to baseline after PRP.
case_images: 10.1177_25158414211035860-fig2.jpg
case_images: PMC8366200_01_10.1177_25158414211035860-fig2.jpg
case_images: fig2-25158414211035860
case_images: Change in 6-mm central macular volume relative to baseline after PRP.
case_images: 10.1177_25158414211035860-fig3.jpg
case_images: PMC8366200_01_10.1177_25158414211035860-fig3.jpg
case_images: fig3-25158414211035860
case_images: A representative example of spectral-domain OCT testing showing baseline macular thickness and volume (a), a subsequent increase in thickness and volume at month 3 after PASCAL PRP (b), and then a return to approximate baseline levels at month 6 (c) with observation only (no anti-VEGF or focal laser treatment).
case_images: 10.1177_25158414211035860-fig4.jpg
case_images: PMC8366200_01_10.1177_25158414211035860-fig4.jpg
case_images: fig4-25158414211035860
case_images: Change in visual acuity after PRP.
case_images: 10.1177_25158414211035860-fig5.jpg
case_images: PMC8366200_01_10.1177_25158414211035860-fig5.jpg
case_images: fig5-25158414211035860
case_images: However, the difference at 6 months was not statistically significant:0.460-0.502 (p = 0.244) (Figure 5).